In response to the recent TMR Capping notification for Anti-Cancer Non Scheduled formulations, we have reduced MRPs of our products effective 09th November 2026. This move not only aligns with regulatory changes but also reflects our commitment to making quality healthcare more affordable and accessible.

“All channel partners are advised to bill at the reduced rates and ensure that the benefit of reduction is correctly passed on to end-users. This is not only about complying with regulations but also demonstrates our dedication to fair business practices.”